The Human Variable 

CYNAERA REPURPOSED™ accelerates drug discovery for infection-associated chronic conditions like Long COVID and ME/CFS. Using AI-driven terrain modeling, it cuts repurposing timelines from years to weeks—identifying multi-indication therapies, reducing cost by up to 90%, and advancing patient-ready treatments through intelligent simulation.

The Physics of Survival reframes human stability as the core infrastructure of civilization. This white paper introduces Terrain Intelligence—a unifying systems framework that links space medicine, chronic illness, and climate resilience under one predictive model. Drawing on NASA Human Research Program findings and longitudinal public-health data, Cynthia Adinig demonstrates that physiological collapse in microgravity mirrors the same autonomic and immune failure seen in Lon

Remission in ME/CFS is often described as spontaneous, yet nothing about it is random. The illusion of rarity comes from measurement bias. We record symptoms, not trajectory. When patient data is plotted longitudinally rather than episodically, a clear pattern emerges. Remission occurs when the body’s internal feedback systems, immune, autonomic, and metabolic, temporarily synchronize

This white paper argues that MCS and MCAS are vantage points on a shared hypersensitivity terrain, proposing a new classification, Multi-Chemical and Environmental Hypersensitivity Disorders (MCEHD), that unites them, honors patient ingenuity, and formalizes my frameworks.

The CYNAERA ESA (Emergency Stabilization Authorization) framework presents a solution. During a declared emergency, ESA enables states and FEMA to pre-authorize qualified clinics to operate as temporary micro-ERs and reimburse those services as emergency protective measures. Critically, ESA does not require new legislation. It strategically aligns existing authorities under the Stafford Act for federal disaster declarations, FEMA Public Assistance Category B for emergency pro

ME/CFS is a relapsing, multisystem condition characterized by immune disruption, neuroinflammation, autonomic dysfunction, and energy metabolism abnormalities. Trials should anchor in stabilization before pursuing cure.